Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study

NCT01621724 is registered in ClinicalTrials.gov with Cell Medica Ltd as lead sponsor.

NCT NCT01621724
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01621724 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study
Lead sponsor
Cell Medica Ltd
Phase
Phase 1/2
Overall status
Completed
Start date
April 30, 2012
Completion date
May 31, 2018
Enrollment
7 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukaemia, chronic myeloid leukaemia